In situ cancer vaccination refers to any approach that exploits tumour antigens available at a
tumour site to induce tumour-specific adaptive immune responses. These approaches hold …

In 2015, oncolytic virotherapy was approved for clinical use, and in 2017, recombinant
adeno-associated virus (AAV) delivery was also approved. However, systemic …

Antigen cross‐priming of CD8+ T cells is a critical process necessary for the effective
expansion and activation of CD8+ T cells endowed with the ability to recognize and destroy …

Oncolytic viruses (OVs), viruses engineered to lyse tumor cells, work hand in hand with the
immune response. While for decades the field isolated lytic capability and viral spread to …

Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …

Immunotherapy is considered to be an effective treatment for cancer and has drawn
extensive interest. Nevertheless, the insufficient antigenicity and immunosuppressive tumor …

There is a critical unmet need for safe and efficacious neoadjuvant treatment for cisplatin-
ineligible patients with muscle-invasive bladder cancer. Here we launched a phase 1b study …

Dendritic cells (DCs) are sentinel immune cells that form a critical bridge linking the innate
and adaptive immune systems. Extensive research addressing the cellular origin and …

Abstract Purpose: GS-3583, an FMS-like tyrosine kinase 3 (FLT3) agonist Fc fusion protein,
expanded conventional dendritic cells (cDC) in the periphery of healthy volunteers …

Dendritic cells (DCs) are professional antigen-presenting cells that play a key role in
shaping adaptive immunity. DCs have a unique ability to sample their environment, capture …